Pomalidomide-6-OH is primarily utilized in the field of oncology, particularly in the treatment of multiple myeloma. It is an active metabolite of pomalidomide, which enhances its therapeutic effects by modulating the immune system and inducing apoptosis in cancer cells. This compound is often employed in combination with other medications, such as dexamethasone, to improve outcomes in patients who have not responded adequately to previous treatments. Its mechanism involves inhibiting angiogenesis and promoting the degradation of specific proteins essential for cancer cell survival. Additionally, it is being investigated for potential applications in other hematologic malignancies and autoimmune disorders due to its immunomodulatory properties.